Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

par Dieplinger, H, Schoenfeld, P Y, Fielding, C J
Publié 1986

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

par Pimentel, M., Cash, B. D., Lembo, A., Wolf, R. A., Israel, R. J., Schoenfeld, P.
Publié dans Dig Dis Sci (2017)

Erratum to: Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

par Pimentel, M., Cash, B. D., Lembo, A., Wolf, R. A., Israel, R. J., Schoenfeld, P.
Publié dans Dig Dis Sci (2017)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials...

par Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., Forbes, W. P.
Publié 2014

Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial

par Zolotarevsky, E., Fehmi, S. M., Anderson, M. A., Schoenfeld, P. S., Elmunzer, B. J., Kwon, R. S., Piraka, C. R., Wamsteker, E.-J., Scheiman, J. M., Korsnes, S. J., Normolle, D. P., Kim, H. Myra, Elta, G. H.
Publié 2011